Price$20.16-0.46 (-2.21%)
01:30 PM06:00 PM
News · 26 weeks51+44%
2025-12-142026-06-07
Mix3290d
- SEC Filings15(47%)
- Insider13(41%)
- Other2(6%)
- Analyst2(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Mcgraw Benjamin F Iii4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Director Kirsch Arthur S4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERDirector Cohen David E sold $123,094 worth of shares (6,056 units at $20.33) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 17,609 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERChief Scientific Officer Patel Jeegar Pravinkumar sold $379,462 worth of shares (16,687 units at $22.74) as part of a pre-agreed trading plan and exercised 13,512 shares at a strike of $3.84, decreasing direct ownership by 6% to 46,403 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERPresident & CEO Pena Luis C. sold $381,736 worth of shares (16,787 units at $22.74) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 637,896 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Evommune, Inc. (0002044725) (Filer)
- INSIDERChief Business & Legal Officer Moss Gregory S. exercised 14,223 shares at a strike of $1.71 and sold $324,711 worth of shares (14,223 units at $22.83) as part of a pre-agreed trading plan (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERChief Financial Officer Carver Kyle exercised 15,000 shares at a strike of $2.99 and sold $415,117 worth of shares (18,175 units at $22.84) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 59,335 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form 10-Q filed by Evommune Inc.10-Q - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Reports First Quarter 2026 Financial Results and Provides Business Highlights‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials ‑ Phase 2b clinical trial evaluating a subcutaneous formulation of EVO301 in AD planned, following positive proof-of-concept (POC) data reported in February 2026 ‑ Plans to initiate a Phase 2b dose-ranging clinical trial of EVO756 in migraine prophylaxis in mid-2026 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first q
- ANALYSTStifel initiated coverage on Evommune with a new price targetStifel initiated coverage of Evommune with a rating of Buy and set a new price target of $54.00
- SECSEC Form EFFECT filed by Evommune Inc.EFFECT - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form DEFA14A filed by Evommune Inc.DEFA14A - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form DEF 14A filed by Evommune Inc.DEF 14A - Evommune, Inc. (0002044725) (Filer)
- INSIDERSEC Form 4 filed by Patel Jeegar Pravinkumar4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Drew Janice Suzann4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Bauer Eugene4 - Evommune, Inc. (0002044725) (Issuer)
EVMN FAQ
6 questionsWhere does EVMN stock trade?
Evommune Inc. (EVMN) is listed on NYSE.What sector and industry is EVMN in?
Evommune Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Evommune Inc. go public?
Evommune Inc. (EVMN) completed its IPO in 2025.What are analysts saying about EVMN?
Evommune Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy on 2026-05-01. Recent price targets range from $3500.00 to $4200.00.What companies are similar to EVMN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EVMN side-by-side with any of them on Quantisnow.How can I track EVMN on Quantisnow?
Quantisnow aggregates Evommune Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVMN to receive live email and push alerts on every new disclosure.